Streetwise Reports' Article Archives — July 2021 back to current month (23)
The latest developments concerning Sorrento Therapeutics, its product portfolio and partners are summarized in a Dawson James Securities report.
The purpose of HTG Molecular Diagnostics' new therapeutics division and early interest in the biopharma's commercial-ready Transcriptome Panel are covered in an H.C. Wainwright & Co. report.
Knox Henderson takes a close look at Rritual Superfoods and its plans to ramp up mass distribution.
Shares of Tilray Inc. traded 25% higher after the company reported FY/21 financial results that included a 27% YoY increase in net revenues to $513.1 million driven by a 55% growth in cannabis revenue following its Aphria acquisition.
As legalization takes hold across the U.S., opportunities for the next generation of cannabis companies expand. Adrian Morante of K2 & Associates finds “trustworthy, capable and reputable” companies with value.
The investment thesis for the device company Carmat, whose therapy "allows patients to live with almost normal quality of life," is presented in an H.C. Wainwright & Co. report.
A Roth Capital Partners report calls this a "very cost-effective and strategic move" for Daré Bioscience.
Reliq Health Technologies advised it entered into agreements with three physician practices in Texas for its iUGO Care platform.
HCA Healthcare shares established a new 52-week high after the company reported a greater than 30% increase in YoY revenue in Q2/21.
Immunome's proprietary discovery engine identifies novel therapeutic antibodies and their targets.
Cytokinetics Inc. shares reached a new 52-week high after the company reported positive topline results from its Phase 2 CK-274 hypertrophic cardiomyopathy clinical trial.
Zynex Inc. shares traded 10% higher after the electrotherapy medical device maker reported a 247% YoY growth in orders during Q2/21 and raised the range for its EBITDA estimates in the quarter by $1.2 million.
Merger of Two Biopharmas 'Brings a New Dawn' (07/14/2021)
The implications of the Aerpio Pharmaceuticals–Aadi Bioscience transaction and the outlook and future for the combined company's lead drug candidate are discussed in an H.C. Wainwright & Co. report.
The recent news regarding Can-Fite BioPharma is reviewed in a Dawson James Securities report.
McAlinden Research Partners expects activity and revenues in the cannabis space to continue ramping up as the US crosses the point at which legalization is not a question of "if" but "when."
Alphatec Holdings Inc. shares traded 12% higher after the company reported preliminary Q2/21 financial results that included a larger than 90% increase in YoY organic revenue.
Algernon Pharmaceuticals CEO Christopher J. Moreau and Dr. David Nutt, the company's research stroke consultant, discuss Algernon's upcoming Phase 1 study of DMT for stroke.
A review of Daré Bioscience's lead clinical product for bacterial vaginosis and a potential timeline to commercialization are provided in a Roth Capital Partners report.
The encouraging work Regeneron Pharmaceuticals completed thus far, and the next challenge in this program, are laid out in an H.C. Wainwright & Co. report.
Shares of Biohaven Pharmaceutical Holding Co. Ltd. traded 12% higher to a new 52-week high after the company reported preliminary Q2/21 net product revenue of $93 million for NURTEC ODT, which it claims is the first and only FDA approved medicine for both acute and preventive migraine treatment.
Shares of ALX Oncology Holdings Inc. traded 10% higher after the company reported new data from its Phase 1b ASPEN-01 study of ALX148 demonstrated a robust objective response in patients with gastric or gastroesophageal junction cancer.
Alector Inc. shares traded 59% higher after the company announced it entered into a global collaboration agreement with GlaxoSmithKline to develop and advance two first-in-class, clinical stage monoclonal antibodies for treating neurodegenerative diseases including frontotemporal dementia, amyotrophic lateral sclerosis, Parkinson's and Alzheimer's.
Pulse Biosciences shares traded 27% higher after the company announced it secured a $50 million private placement one day after it reported the first CellFX® procedure using its proprietary Nano-Pulse Stimulation technology had been performed in Canada.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|